Current regulatory and market environment for biosimilars in Serbia

Open access


Background: Biosimilars are currently a reality of the pharmaceutical market in the European Union. This paper describes the current regulatory policy for approving biosimilars both in the European Union and in Serbia, which is not a Member State. Also, a comprehensive analysis on biosimilars consumption data on the Serbian market has been performed.

Methods: The European Medicines Agency has established a series of biosimilar scientific guidelines that comprises a regulatory policy for biosimilars in the European Union. This has enabled different biosimilar products to be marketed, making the European Union biosimilar market the most developed one globally. In the paper, this regulatory environment has been analysed, emphasising all relevant biosimilar guidelines as well as marketed biosimilar medicines. Also, an analysis is performed on Serbian regulatory requirements for approving and marketing biosimilars, analysing the Serbian regulatory authority’s consumption data as well as data available from the National Health Insurance Institution.

Results: In the paper, the comprehensive analysis of the current European Union as well as Serbian regulatory environment has been presented, with a special emphasis on the Serbian market potential for biosimilar medicines. Detailed consumption data has been analysed for the period 2007-2011.

Conclusion: Serbia has good potential for biosimilar products, which is supported by national health insurance policy and the general trend of cutting the reimbursement costs for prescription medicines. Five year consumption data for biosimilars in Serbia shows that the Serbian biosimilars market is very small in terms of market share values, especially comparing to other large European biosimilar markets.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Giezen TJ Mantel-Teeuwisse AK Straus SM Schellekens H Leufkens HG Egberts AC. Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Assoc 2008; 300: 1887-96.

  • 2. EvaluatePharma® World Preview to 2012 6 June 2008.

  • 3. Kresse GB. Biosimilars - science status and strategic perspective. Eur J Pharm Biopharm 2009; 72: 479-86.

  • 4. Grabowski HG Ridley DB Schulman KA. Entry and competition in generic biologics. Managerial Decis Econ 2007; 28: 439-51.

  • 5. Commission Regulation (EC) No. 726/2004 of 31 March 2004. Available February 7 2013 at: PDF.

  • 6. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004. Available May 17 2013 at: 36:0034:0057:en:PDF.

  • 7. European Medicines Agency. Multidisciplinary: biosimilars. Available May 14 2013 at: content_000408.jsp.

  • 8. European Medicines Agency. Guideline on similar biological medicinal product (CHMP/437/04). EMA 2005.

  • 9. Zuniga L Calvo B. Biosimilars approval process. Regul Toxicol Pharmacol 2010; 56: 374-7.

  • 10. Zuniga L Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol 2009; 27: 385-7.

  • 11. Braido F Holgate S Canonica GW. From “blockbusters” to “biosimilars”: an opportunity for patients medical specialists and health care providers. Pulm Pharmacol Ther 2012; 25: 483-6.

  • 12. Roger SD Goldsmith D. Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther 2008; 33: 459-64.

  • 13. Haussler B. Cost savings potential of biosimilars in the German health care system. In: Life science in the capital market biosimilars. DVFA 2010.

  • 14. Datamonitor biosimilars: strategic issues - potential remains unknown Report No. DMHC2337. Datamonitor London 2007.

  • 15. IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS 2011: 4-5.

  • 16. Pejovic G Filipovic J Tasic Lj. How to remove barriers to medicines trade in emerging economies: the role of medicines regulatory authority in Serbia. Accred Qual Assur 2011; 16: 253-61.

  • 17. Business Monitor International. Serbia pharmaceuticals and healthcare report Q1 2013. Available February 10 2013 at: http://

  • 18. Adamski J Godman B Ofierska-Sujkowska G Wendykowska K Laius O Jan S et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010; 10: 153-68.

  • 19. Medicines and Medical Devices Agency of Serbia. Medicine consumption and market data for 2007. Available February 16 2013 at:

  • 20. Medicines and Medical Devices Agency of Serbia. Medicine consumption and market data for 2008. Available February 16 2013 at:

  • 21. Medicines and Medical Devices Agency of Serbia. Medicine consumption and market data for 2009. Available February 16 2013 at:

  • 22. Medicines and Medical Devices Agency of Serbia. Medicine consumption and market data for 2010. Available February 16 2013 at:

  • 23. Medicines and Medical Devices Agency of Serbia. Medicine consumption and market data for 2011. Belgrade: Medicines and Medical Devices Agency of Serbia 2012.

  • 24. National Health Insurance Institution. Positive medicine lists. Available February 5 2013 at: ekovi-actual/02012013.

  • 25. Generics and Biosimilars Iniciative. European uptake of biosimilars. Available May 16 2013 at: biosimilar%20uptake.

  • 26. Declerck PJ Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars 2012; 2: 33-40.

  • 27. European Commission. What you need to know about biosimilar medicinal product a consensus information document. Available May 20 2013 at:

Journal information
Impact Factor

IMPACT FACTOR 2018: 1.074
5-year IMPACT FACTOR: 0.728

CiteScore 2018: 0.94

SCImago Journal Rank (SJR) 2018: 0.564
Source Normalized Impact per Paper (SNIP) 2018: 0.478

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 252 152 3
PDF Downloads 111 73 2